Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

FOCAL THERAPY The Role of the Tumor Microenvironment in Prostate Cancer Focal Therapy

By: Pier Paolo Avolio, MD, McGill University, Montréal, Quebec, Canada; Petr Macek, MD, PhD, Institute Mutualiste Montsouris, Paris, France; Ashutosh Tewari, MBBS, MCh, FRCS (Hon), Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, New York; Rafael Sanchez-Salas, MD, McGill University, Montréal, Quebec, Canada | Posted on: 09 Jun 2023

As with many other cancers, development, progression, and therapeutic response in prostate cancer (PCa) are significantly influenced by the cross-talk between cancerous cells and the surrounding tumor microenvironment (TME).1 The TME is a highly complex system in which the tumor dynamically interacts with several host cells. The host components include stromal cells, extracellular matrix, endothelial and vascular cells, immune cells, and various soluble factors such as interleukin 6 and receptor activator of nuclear factor κB ligand.2 Tumor cells within the TME can transform the extracellular matrix, stimulating angiogenesis and releasing growth factors and fibroblasts. As this dramatic stromal reaction increases, tumor aggressiveness rises, as indicated by the growth of the Gleason score, which represents an indicator of adverse clinical outcomes and recurrence.3 Indeed, histological studies demonstrated the infiltration of TME host immune cells in almost 90% of PCa specimens.4 The impact of the host immune system on cancer outcomes is very complex, as the innate and adaptive immune responses can both provide antineoplastic activity and enhance the propagation of carcinogenesis.5 For instance, cytotoxic T lymphocytes, commonly found in TME, secrete transforming growth factor-β, which both supports tumor growth and induces immune suppression.4 Therefore, manipulation of TME through inhibition or activation of specific molecular and cellular targets has been extensively studied in cancer therapy.

In PCa, the most investigated model of TME modulation is androgen deprivation therapy (ADT).6 Androgens lead to continuous activation of the androgen receptor in PCa cells and promote an immunosuppressive TME. ADT, by blocking the steroidogenesis, causes TME changes that appear to improve the outcome of external beam radiotherapy in terms of overall survival, with wide application in clinical practice.7

We strongly believe that this beneficial effect of TME manipulation could be applied to other PCa treatments. Therefore, TME could also become a key target of PCa focal therapies, which are ablative techniques using various technologies such as high-intensity focused ultrasound (HIFU), cryotherapy, photodynamic therapy (PDT), and irreversible electroporation (IRE). Each of these techniques has proven and inherent TME response that may be potentially enhanced by systemic therapy (see Figure). For instance, HIFU could provide an initial boost to the immunotherapeutic treatment of PCa.1 The main effect of HIFU is thermal ablation by heating the tumor tissue above about 60 °C, resulting in coagulative necrosis and cavity creation.8 Thermal energy destroys cancerous tissue at the delivery site leading to a dramatic reduction of the microcirculatory bed; the higher the degree of reduction, the lower the probability of relapse.9 Besides, mechanical damage leads to the release of danger signals, such as damage-associated molecular patterns and the activation of heat shock proteins, with relevant changes in TME and immune response.1 Heat shock proteins, such as HSP60, operate as molecular chaperones for exogenous antigens released during mechanical lysis. Antigens chaperoned by HSP60 may activate dendritic cells, leading to cytotoxic T cell (CTL) infiltration and tumor killing.10 The immunotherapeutic efficacy of HIFU has been studied in many types of cancer. Hu et al confirmed that HIFU enhances the infiltration of dendritic cells (DCs) into the TME of mice with colon adenocarcinoma, suggesting combining this procedure with other therapies to achieve better clinical outcomes.11 Similarly, Ran et al demonstrated that HIFU increases cluster of differentiation (CD)3+ and CD4+ levels into TME and thereby suppresses tumor growth and progression of PCa mice.12

Figure. The impact of androgen deprivation therapy and focal therapy on prostate tumor microenvironment. Focal therapy procedures have the potential to enhance tumor-specific antigen presentation by hindering tumor-negative immune regulation and triggering T-cell response to cancer. Focal therapy procedures enhance the function of dendritic cells by increasing antigen uptake and efficient antigen presentation to T cells. It also induces immunogenic tumor cell death by enhancing tumor-killing properties of natural killer cells and cytotoxic lymphocytes. Dying tumor cells release damage-associated molecular patterns (DAMPs) that further activate innate immune responses by releasing antitumor cytokines and enhanced phagocytosis by macrophages and dendritic cells. BC indicates fibroblastic cell; CD, cluster of differentiation; CTL, cytotoxic T cell; DC, dendritic cell; ECM, extracellular matrix; HIFU, high-intensity focused ultrasound; HSP, heat shock proteins; IL, interleukin; IRE, irreversible electroporation; MDSC, myeloid-derived suppressor cell; NK, natural killer, PDT, photodynamic therapy; RANKL, receptor activator of nuclear factor κB ligand; TGFβ, transforming growth factor-β; Tregs, regulatory T cells.

Another focal therapy for PCa whose effect is mediated by changes in the TME is cryotherapy, which deploys extremely low temperatures to induce both necrosis and apoptosis of tumor cells.8,13 Oppositely to high-temperature ablation techniques, cryotherapy enhances the immune response by preserving tumor antigens and cytokines.4 A growing body of evidence suggests that necrosis, occurring mainly in the inner zone of the tissue, leads tumor cells to release damage-associated molecular patterns, triggering the immune response through the maturation of DCs and, consequently, CTL activation.4 However, apoptosis, which occurs mainly in the peripheral margin of the ablated organ, leads to a lack of secretion of danger signals, thus contributing to immunosuppression.14 Cerqueira et al investigated the TME changes before and after cryoablation showing a significant increase in CTLs.13 Furthermore, Ross et al examined cryotherapy combined with ADT and pembrolizumab, showing greater local control of low to intermediate risk disease.15 This study represents a great example of symbiotic action with ablation and systemic therapy.

Similarly, tumor cell necrosis is the goal of PDT, another focal therapy technique that deploys a specific wave length laser to trigger the photosensitizer and therefore generate reactive oxygen species.4 The immunological effect achieved by PDT is exacerbated in the TME, with the attraction of neutrophils, DCs, and macrophages, which activate CTLs and natural killer cells against cancerous cells and lead to the secretion of interleukin (IL)-1, IL-6, IL-8, IL-10, and IL-12.16 A preclinical mouse model of PCa suggested that combining PDT with an anticholinergic stimulating factor can inhibit myeloid tumor infiltration into TME, thus improving overall survival and reducing tumor growth.4

Additionally, IRE is a PCa focal therapy that employs electrical impulses to disrupt cell membranes.8 Due to this controlled, nonthermal energy delivery mechanism, vascular tissue can be preserved during IRE treatment, potentially increasing tumor infiltration of CD8+ CTLs8 into TME. IRE decreases regulatory T cells and myeloid-derived suppressor cells in the TME.17 Similarly, Burbach et al explored the combination of IRE and checkpoint inhibitors in PCa mice, which were associated with increased tumor-specific CD8+ T cells in the blood and TME.18

In summary, focal therapy outcomes as known today could be improved with a combination of energies and a systemic treatment option like ADT.5 The results of ongoing prospective studies (CHRONOS trial and ENHANCE trial) are awaited to confirm these findings.19,20 Furthermore, novel approaches like the one explored in the RTIRE trial (NCT 05345444) will shed light on the potential combination of energy (IRE) and a lower dose of radiotherapy (32.5 Gy in 5 fractions). We feel that improved assessment and intervention of TME are critical to the development of effective focal therapies for PCa to consolidate cancer control without affecting functional outcomes.

  1. Nair SS, Weil R, Dovey Z, et al. The tumor microenvironment and immunotherapy in prostate and bladder cancer. Urol Clin North Am. 2020;47(4):e17-e54.
  2. Dai J, Lu Y, Roca H, et al. Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer. 2017;36(1):29.
  3. Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912-2923.
  4. Karwacki J, Kiełbik A, Szlasa W, et al. Boosting the immune response-combining local and immune therapy for prostate cancer treatment. Cells. 2022;11(18):2793.
  5. Giraldo NA, Sanchez-Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45-53.
  6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002;167(2 Part 2):948-952.
  7. Singh S, Moore CM, Punwani S, et al. Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24(3):612-622.
  8. Tourinho-Barbosa RR, de la Rosette J, Sanchez-Salas R. Prostate cancer multifocality, the index lesion, and the microenvironment. Curr Opin Urol. 2018;28(6):499-505.
  9. Borges RC, Tourinho-Barbosa RR, de la Rosette J. Tumour microenvironment and focal therapy for prostate cancer. Curr Opin Urol. 2022;32(3):248-253.
  10. Hu Z, Yang XY, Liu Y, et al. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun. 2005;335(1):124-131.
  11. Hu Z, Yang XY, Liu Y, et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med. 2007;5(1):34.
  12. Ran L-F, Xie X-P, Xia J-Z, et al. Specific antitumour immunity of HIFU-activated cytotoxic T lymphocytes after adoptive transfusion in tumour-bearing mice. Int J Hyperthermia. 2016;32(2):204-210.
  13. Cerqueira MA, Ferrari KL, de Mattos AC, et al. T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation. World J Urol. 2020;38(3):673-680.
  14. Aarts BM, Klompenhouwer EG, Rice SL, et al. Cryoablation and immunotherapy: an overview of evidence on its synergy. Insights Imaging. 2019;10(1):53.
  15. Ross AE, Hurley PJ, Tran PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(1):184-193.
  16. Kabingu E, Vaughan L, Owczarczak B, et al. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer. 2007;96(12):1839-1848.
  17. Kiełbik A, Szlasa W, Saczko J, et al. Electroporation-based treatments in urology. Cancers. 2020;12(8):2208.
  18. Burbach BJ, O’Flanagan SD, Shao Q, et al. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. Nat Commun. 2021;12(1):3862.
  19. Reddy D, Shah TT, Dudderidge T, et al. Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): a prospective, multi-centre therapeutic phase II parallel randomised control trial. Contemp Clin Trials. 2020;93:105999.
  20. Marra G, Dell’oglio P, Baghdadi M, et al. Multimodal treatment in focal therapy for localized prostate cancer using concomitant short-term androgen deprivation therapy: the ENHANCE prospective pilot study. Minerva Urol Nefrol. 2019;71:544-548.